http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
He-Xin Zhang,윤근병,이영주,박준려,이동호 한국고분자학회 2011 Macromolecular Research Vol.19 No.6
Polymerization of propylene was carried out using a MgCl_2-supported TiCl_4 catalyst in conjunction with triethylaluminium (TEA) as the cocatalyst and various types of alkoxy silane compounds as an external donor. The effect of the external donor on the performance of the catalyst with different internal donors was investigated. The polydispersity index (PDI) of polypropylene (PP) obtained with the diether and succinate based catalyst were decreased with the introduction of an external donor and the PDI increased for the phthalate based catalyst. The molecular weight and PDI increased with the introduction of an external donor. The highest PDI of PP was obtained by polymerization with di-n-propyldimethoxysilane (DnPDMS) as an external donor. In addition, a mixture of external donors was used to control the PDI of PP and the composition of the catalyst was examined after treated with TEA/external donor. Furthermore, the theoretical PDI value was calculated for a mixture of external donor systems. The PDI of PP could be controlled and predicted while retaining high activity, high isospecificity and high molecular weight by changing the structure of the external donor and/or their mixture.
Zhang, Hao,Liu, Jing-Sheng,Zhang, He-Xin,Ko, Eun-Bin,Park, Jae-Hyeong,Moon, Young-Kwon,Shin, Byeong-Kwang,Zhang, Xue-Quan,Yoon, Keun-Byoung American Scientific Publishers 2018 Journal of Nanoscience and Nanotechnology Vol.18 No.4
<P>A facile coagglomeration method for preparing a long alkyl chain modified graphene oxide (MGO)/MgCl2-supported Ti-based Ziegler-Natta catalyst was reported. The effects of MGO on the catalyst morphology and activity for ethylene polymerization were examined. The resultant polyethylene (PE)/MGO nanocomposites exhibited a layered morphology, with the MGO fillers being well dispersed and exhibiting strong interfacial adhesion to the PE matrix. The thermal stability and mechanical properties of the PE were significantly enhanced with the introduction of a small amount of the MGO filler. Thus, this work provides a facile approach to the production of high-performance PE.</P>
Zhang, He-xin,Park, Jae-Hyeong,Yoon, Keun-Byoung Elsevier 2018 Composites science and technology Vol.154 No.-
<P><B>Abstract</B></P> <P>Superior electrically conductive PE nanocomposites were prepared with reduced graphene oxide(rGO)-supported MAO cocatalyst via <I>in situ</I> ethylene polymerization. The electrical conductivity of the composites was very high at 1.2 S/m. This value is the highest among reported rGO-filled composites. The cocatalyst system was prepared by modifying with alkoxysilane compound to prevent restacking of the GO plane in the reduction process and solvothermal reduction of GO. The effect of cocatalysts on the properties of nanocomposites and distribution of nanosheets in the polymer matrix was investigated in detail. The mechanical properties and thermal stability of PE/rGO nanocomposites were significantly increased via the addition of a small amount of rGO. These properties resulted from the restacked rGO layers exfoliated <I>in situ</I> by the ethylene insertion between the intercalated layers.</P>
Zhang, Hao,Moon, Young-Kwon,Zhang, Xue-Quan,Liu, Jing-Sheng,Zhang, He-Xin,Yoon, Keun-Byoung Pergamon Press 2017 European polymer journal Vol.87 No.-
<P><B>Abstract</B></P> <P>A facile method for preparing polyethylene (PE)/octadecylamine-functionalized MoS<SUB>2</SUB> (ODA-MoS<SUB>2</SUB>) nanocomposites through in situ polymerization with an ODA-MoS<SUB>2</SUB>-MgCl-TiCl<SUB>4</SUB> catalyst was developed. The catalyst was synthesized simply by the treatment of ODA-MoS<SUB>2</SUB> with a Grignard reagent, followed by anchoring of a TiCl<SUB>4</SUB> catalyst. The resulting catalyst exhibited higher activity toward ethylene polymerization than did an ODA-MoS<SUB>2</SUB>-free catalyst. After polymerization, the resultant PE/ODA-MoS<SUB>2</SUB> nanocomposites reproduced the catalyst morphology, showing a flaked morphology. In addition, the thermal stability and mechanical properties of PE were significantly enhanced by the introduction of ODA-MoS<SUB>2</SUB> fillers. These properties could result from the good dispersion and strong interfacial adhesion of ODA-MoS<SUB>2</SUB> fillers and the PE matrix.</P> <P><B>Highlights</B></P> <P> <UL> <LI> PE/ODA-MoS<SUB>2</SUB> nanocomposites were successful synthesized through in-situ polymerization. </LI> <LI> The resultant nanocomposites had a layered morphology. </LI> <LI> The ODA-MoS<SUB>2</SUB> fillers well dispersed in the PE matrix with strong interfacial adhesion. </LI> <LI> The thermal stability and mechanical properties of PE were significantly enhanced with the addition of ODA-MoS<SUB>2</SUB>. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer
Zhang, Xin-Ji,Zhang, Tian-Yi,Yu, Fei-Fei,Wei, Xin,Li, Ye-Sheng,Xu, Feng,Wei, Li-Xin,He, Jia Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.11
Background: Fatal adverse events (FAEs) have been reported with sorafenib, a vascular endothelial growth factor receptor kinase inhibitor (VEGFR TKI). We here performed an up-to-date and detailed meta-analysis to determine the overall risk of FAEs associated with sorafenib. Methods: Databases, including PubMed, Embase and Web of Science, and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies. Eligible studies included randomized controlled trials evaluating sorafenib effects in patients with all malignancies. Summary incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated for FAEs. In addition, subgroup analyses were performed according to tumor type and therapy regimen. Results: 13 trials recruiting 5,546 patients were included in our analysis. The overall incidence of FAEs with sorafenib was 1.99% (95%CI, 0.98-4.02%). Patients treated with sorafenib had a significantly increased risk of FAEs compared with patients treated with control medication, with an RR of 1.77 (95%CI 1.25-2.52, P=0.001). Risk varied with tumour type, but appeared independent of therapy regimen. A significantly increased risk of FAEs was observed in patients with lung cancer (RR 2.26; 95% CI 1.03-4.99; P= 0.043) and renal cancer (RR 1.84; 95% CI 1.15-2.94; P= 0.011). The most common causes of FAEs were hemorrhage (8.6%) and thrombus or embolism (4.9%). Conclusions: It is important for health care practitioners to be aware of the risks of FAEs associated with sorafenib, especially in patients with renal and lung cancer.